Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

M. Saleh, M. Barve, V. Subbiah, K. P. Papadopoulos, D. Morgensztern, N. B. Mettu, S. Roychowdhury, I. Spanggaard, M. L. Veronese, C. Tian, I. M. Silverman, M. Gutierrez

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science